|
gptkbp:instance_of
|
gptkb:botulism
|
|
gptkbp:administered_by
|
injection
|
|
gptkbp:approves
|
gptkb:2009
gptkb:FDA
|
|
gptkbp:available_in
|
vials
|
|
gptkbp:clinical_trial
|
Phase IV
Phase III
|
|
gptkbp:clinical_use
|
therapeutic procedures
aesthetic procedures
|
|
gptkbp:contraindication
|
infection at injection site
neuromuscular disorders
allergy to botulinum toxin
|
|
gptkbp:dosage_form
|
injectable solution
|
|
gptkbp:duration
|
as needed
up to 4 months
every 3 to 4 months
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Dysport
|
|
gptkbp:ingredients
|
gptkb:abobotulinumtoxin_A
|
|
gptkbp:invention
|
patented
|
|
gptkbp:manufacturer
|
gptkb:Ipsen
|
|
gptkbp:marketed_as
|
gptkb:Europe
gptkb:Australia
gptkb:Canada
gptkb:United_States
gptkb:Azzalure
|
|
gptkbp:mechanism_of_action
|
muscle paralysis
|
|
gptkbp:patient_population
|
adults
children with spasticity
|
|
gptkbp:premiered_on
|
2 to 3 days
|
|
gptkbp:provides_guidance_on
|
gptkb:American_Society_of_Plastic_Surgeons
gptkb:European_Academy_of_Neurology
gptkb:American_Academy_of_Neurology
|
|
gptkbp:reconstitution_required
|
gptkb:true
|
|
gptkbp:related_to
|
gptkb:Botox
gptkb:Jeuveau
gptkb:Xeomin
|
|
gptkbp:research_focus
|
cost-effectiveness
patient satisfaction
safety profile
long-term efficacy
comparative studies with Botox
|
|
gptkbp:side_effect
|
headache
nausea
muscle weakness
dry mouth
pain at injection site
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:used_for
|
gptkb:cosmetics
chronic migraine
muscle spasticity
|
|
gptkbp:website
|
facial muscles
forehead
crow's feet
glabellar lines
neck muscles
|
|
gptkbp:bfsParent
|
gptkb:Botox
|
|
gptkbp:bfsLayer
|
6
|